Search

Your search keyword '"Furmaniuk, Anna"' showing total 15 results
Start Over Author "Furmaniuk, Anna"
15 results on '"Furmaniuk, Anna"'

3. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Author

Pigeon-Kherchiche, Patricia, Flaus-Furmaniuk, Anna, Bald, Martin, Denzer, Christian, von Schnurbein, Julia, Abawi, Ozair, Blume-Peytavi, Ulrike, Krabusch, Philipp, Mai, Knut, Schnabel, Dirk, Wiegand, Susanna, Flück, Christa E, Schulz, Esther, Voss, Egbert, Bratina, Natasa, Weiss, Katja, Martos-Moreno, Gabriel Á, Danset, Alban, Gougis, Paul, Dubern, Béatrice, Clément, Karine, van den Akker, Erica L.T., Argente, Jesús, Bahm, Allison L, Chung, Wendy K, Connors, Hillori S, De Waele, Kathleen, Farooqi, Ismaa Sadaf, Gonneau-Lejeune, Julie, Gordon, Gregory A, Poitou, Christine, Puder, Lia, Swain, James M, Stewart, Murray W, Yuan, Goujun, Wabitsch, Martin, Kühnen, Peter, van den Akker, Erica, Bahm, Allison, Connors, Hillori, Farooqi, I Sadaf, Gordon, Gregory, Kohlsdorf, Katja, Swain, James, Stewart, Murray, and Yuan, Guojun

Published
2020
Full Text
View/download PDF

5. Sex disparities in COVID-19 outcomes of inpatients with diabetes: insights from the CORONADO study

Author

Tramunt, Blandine, primary, Smati, Sarra, additional, Coudol, Sandrine, additional, Wargny, Matthieu, additional, Pichelin, Matthieu, additional, Guyomarch, Béatrice, additional, Al-Salameh, Abdallah, additional, Amadou, Coralie, additional, Barraud, Sara, additional, Bigot, Edith, additional, Bordier, Lyse, additional, Borot, Sophie, additional, Bourgeon, Muriel, additional, Bourron, Olivier, additional, Charrière, Sybil, additional, Chevalier, Nicolas, additional, Cosson, Emmanuel, additional, Fève, Bruno, additional, Flaus-Furmaniuk, Anna, additional, Fontaine, Pierre, additional, Galioot, Amandine, additional, Gonfroy-Leymarie, Céline, additional, Guerci, Bruno, additional, Lablanche, Sandrine, additional, Lalau, Jean-Daniel, additional, Larger, Etienne, additional, Lasbleiz, Adèle, additional, Laviolle, Bruno, additional, Marre, Michel, additional, Munch, Marion, additional, Potier, Louis, additional, Prevost, Gaëtan, additional, Renard, Eric, additional, Reznik, Yves, additional, Seret-Bégué, Dominique, additional, Sibilia, Paul, additional, Thuillier, Philippe, additional, Vergès, Bruno, additional, Gautier, Jean-François, additional, Hadjadj, Samy, additional, Cariou, Bertrand, additional, Mauvais-Jarvis, Franck, additional, and Gourdy, Pierre, additional

Published
2021
Full Text
View/download PDF

6. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Author

Clément, Karine, primary, van den Akker, Erica, additional, Argente, Jesús, additional, Bahm, Allison, additional, Chung, Wendy K, additional, Connors, Hillori, additional, De Waele, Kathleen, additional, Farooqi, I Sadaf, additional, Gonneau-Lejeune, Julie, additional, Gordon, Gregory, additional, Kohlsdorf, Katja, additional, Poitou, Christine, additional, Puder, Lia, additional, Swain, James, additional, Stewart, Murray, additional, Yuan, Guojun, additional, Wabitsch, Martin, additional, Kühnen, Peter, additional, Pigeon-Kherchiche, Patricia, additional, Flaus-Furmaniuk, Anna, additional, Bald, Martin, additional, Denzer, Christian, additional, von Schnurbein, Julia, additional, Abawi, Ozair, additional, Blume-Peytavi, Ulrike, additional, Krabusch, Philipp, additional, Mai, Knut, additional, Schnabel, Dirk, additional, Wiegand, Susanna, additional, Flück, Christa E, additional, Schulz, Esther, additional, Voss, Egbert, additional, Bratina, Natasa, additional, Weiss, Katja, additional, Martos-Moreno, Gabriel Á, additional, Danset, Alban, additional, Gougis, Paul, additional, Dubern, Béatrice, additional, Clément, Karine, additional, van den Akker, Erica L.T., additional, Bahm, Allison L, additional, Connors, Hillori S, additional, Farooqi, Ismaa Sadaf, additional, Gordon, Gregory A, additional, Swain, James M, additional, Stewart, Murray W, additional, and Yuan, Goujun, additional

Published
2020
Full Text
View/download PDF

7. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study.

Author

Wargny, Matthieu, Potier, Louis, Gourdy, Pierre, Pichelin, Matthieu, Amadou, Coralie, Benhamou, Pierre-Yves, Bonnet, Jean-Baptiste, Bordier, Lyse, Bourron, Olivier, Chaumeil, Claude, Chevalier, Nicolas, Darmon, Patrice, Delenne, Blandine, Demarsy, Delphine, Dumas, Marie, Dupuy, Olivier, Flaus-Furmaniuk, Anna, Gautier, Jean-François, Guedj, Anne-Marie, and Jeandidier, Nathalie

Abstract

Aims/hypothesis: This is an update of the results from the previous report of the CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes) study, which aims to describe the outcomes and prognostic factors in patients with diabetes hospitalised for coronavirus disease-2019 (COVID-19). Methods: The CORONADO initiative is a French nationwide multicentre study of patients with diabetes hospitalised for COVID-19 with a 28-day follow-up. The patients were screened after hospital admission from 10 March to 10 April 2020. We mainly focused on hospital discharge and death within 28 days. Results: We included 2796 participants: 63.7% men, mean age 69.7 ± 13.2 years, median BMI (25th–75th percentile) 28.4 (25.0–32.4) kg/m2. Microvascular and macrovascular diabetic complications were found in 44.2% and 38.6% of participants, respectively. Within 28 days, 1404 (50.2%; 95% CI 48.3%, 52.1%) were discharged from hospital with a median duration of hospital stay of 9 (5–14) days, while 577 participants died (20.6%; 95% CI 19.2%, 22.2%). In multivariable models, younger age, routine metformin therapy and longer symptom duration on admission were positively associated with discharge. History of microvascular complications, anticoagulant routine therapy, dyspnoea on admission, and higher aspartate aminotransferase, white cell count and C-reactive protein levels were associated with a reduced chance of discharge. Factors associated with death within 28 days mirrored those associated with discharge, and also included routine treatment by insulin and statin as deleterious factors. Conclusions/interpretation: In patients with diabetes hospitalised for COVID-19, we established prognostic factors for hospital discharge and death that could help clinicians in this pandemic period. Trial registration: Clinicaltrials.gov identifier: NCT04324736 [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

11. Évaluation de l’impact métabolique d’un programme éducatif intensifie à l’insulinothérapie fonctionnelle versus éducation individuelle classique chez les sujets diabétiques de type 1 sur 24 mois de suivi

Author

Flaus-Furmaniuk, Anna, Université de Lorraine (UL), Université de Lorraine, and Michèle Floriot

Subjects
Éducation des patients, [SDV]Life Sciences [q-bio], Insulinothérapie, Non disponible/Not available, Thèse d'exercice de médecine, Diabètes
Abstract

INTRODUCTION: L’objectif de ce travail était de comparer l’impact métabolique de l’insulinothérapie fonctionnelle (IF) intégrée à un programme intensif d’éducation thérapeutique sur 24 mois versus une éducation individuelle classique (EIC) chez les sujets diabétiques de type 1 (DT1) avec HbA1c >7%. METHODES: 55 patients DT1 ayant bénéficié d’une formation IF et qui présentaient une HbA1c >7% ont été rétrospectivement apparié sur l'âge, le sexe, la durée de diabète, le type de traitement, l'HbA1c et l'indice de masse corporelle avec 55 patients DT1 issus de la base de données des patients suivi annuellement pour leur diabète de type 1 avec une EIC. L’évolution du taux d’HbA1c, du poids et des doses d’insuline ont été comparées à 0, 12 et 24 mois de suivi. RESULTATS: L’équilibre glycémique initial était similaire dans les deux groupes avec une HbA1c à 8.0% (p=0.26). A 12 mois de suivi, dans le groupe IF, le taux d’HbA1c a diminué de 0.2% (p=0.01) et cette amélioration a été maintenue à 24 mois de suivi (HbA1c à 7.8%). Dans le groupe EIC, le taux d’HbA1c était à 8.2% à 24 mois. A la fin du suivi, la différence entre les taux d’HbA1c était significative (p=0.004) en faveur du groupe FIT, la dose totale d’insuline administrée était de 45.4 ± 14.4 dans le groupe FIT vs 50.8 ± 18.5 dans le groupe EIC (p=0.05) et le poids restait stable dans le deux groupes. CONCLUSION: Le programme d’insulinothérapie fonctionnelle a permis d’améliorer significativement le profil métabolique des patients DT 1 sur 24 mois de suivi.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results